Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors.

MLA

Langenberg, Marlies H. G., et al. “Phase I Evaluation of Telatinib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Combination with Irinotecan and Capecitabine in Patients with Advanced Solid Tumors.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 16, no. 7, Apr. 2010, pp. 2187–97. EBSCOhost, https://doi.org/10.1158/1078-0432.CCR-09-2436.

APA

Langenberg, M. H. G., Witteveen, P. O., Roodhart, J. M., Verheul, H. M. W., Mergui-Roelvink, M., van der Sar, J., Brendel, E., Laferriere, N., Schellens, J. H. M., & Voest, E. E. (2010). Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 16(7), 2187–2197. https://doi.org/10.1158/1078-0432.CCR-09-2436

Chicago

Langenberg, Marlies H G, Petronella O Witteveen, Jeanine M Roodhart, Henk M W Verheul, Marja Mergui-Roelvink, Jana van der Sar, Erich Brendel, Nicole Laferriere, Jan H M Schellens, and Emile E Voest. 2010. “Phase I Evaluation of Telatinib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Combination with Irinotecan and Capecitabine in Patients with Advanced Solid Tumors.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 16 (7): 2187–97. doi:10.1158/1078-0432.CCR-09-2436.